Lv2
148 积分 2024-10-14 加入
Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges
10天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
22天前
已完结
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
22天前
已完结
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
26天前
已完结
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis
26天前
已完结
Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia
29天前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
1个月前
已完结
Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation
1个月前
已完结
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
1个月前
已完结
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
1个月前
已完结
皖公网安备34019202002308
